Spexis AG bags money for pivotal Phase III trial

Swiss Spexis AG  has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.

Read more

Novo Nordisk takes over Inversago Pharma Inc.

With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.

Read more

More marine plastics than expected

A Dutch-German team of researchers has found out that the amount of not degradable plastics is lower than estimated but that they persist for longer than previously assumed.

Read more

Sygnature Discovery Ltd acquires leading Canadian CRO

British drug discovery specialist Sygnature Discovery Ltd has taken over Canadian NuChem Sciences Inc., one of North America’s largest discovery CROs

Read more

Enzyme foams morer active and stable

Researchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.

Read more

Neuraxpharm pays US$650m for MS drug commercialisation

TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.

Read more

PureTech Health gets US$11.4m to advance LYT-300

LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.

Read more